With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel

Cell and gene therapy has evolved into one of the biopharma industry's hottest markets with a major splash of investment and a run of approvals likely in the coming years. To meet what's likely to be massive demand for manufacturing capacity, industry experts are calling for "forward-looking" investments—but as one pointed out, those checks aren't easy to write.